Announcement

Lexpert Recognizes 14 Davies Partners as Leading Advisors in Technology and Health Sciences

June 28, 2023

Over 40 companies and investors in the innovation sector turned to Davies in the past 18 months for their most complex transactions, with a combined deal value exceeding US$44 billion. As a result, the 2023 Lexpert Special Edition: Technology and Health Sciences ranks 14 Davies partners among the top advisors in Canada.

Our most notable recent work includes advising:

Technology

  • Shaw Communications in its $26-billion merger with Rogers Communications;
  • Advent International Corporation as Canadian counsel in its US$6.4-billion acquisition of NYSE- and TSX-listed Maxar Technologies Inc., a space technology company;
  • PSP Investments in its investment in D-Wave Systems Inc. for the latter’s merger with a SPAC, DPCM Capital Inc. – a deal with an implied value of US$1.6 billion;
  • SPS Commerce, Inc., an American retail cloud services company, in its US$49-million acquisition of InterTrade Systems Inc., a Canadian SaaS commerce technology solutions company, from mdf commerce inc.;
  • MacKinnon, Bennett & Co. in the C$32-million merger of its portfolio company Bird Canada Inc. with Bird Global, Inc.;
  • Tegus, a leading VC-backed research platform for investors, in its acquisition of Canalyst, a provider of data and analytics on listed companies; and
  • WideOrbit, Inc., a California-based media vertical software provider, in its sale to Constellation Software Inc. and its subsidiary Lumine Group Inc., and the related spin-out of the combined Lumine Group Inc. as a new public company listed on the TSX-V.

Health Sciences

  • BELLUS Health Inc. in its US$2-billion sale to GSK plc, a British-based pharmaceutical company;
  • OMERS Administration Corporation in its US$200-million acquisition of 54.5% stake of global royalties on MAVYRET, from Enanta Pharmaceuticals, Inc.;
  • Nasdaq-listed Shockwave Medical, Inc. as Canadian counsel in its acquisition of Nasdaq- and TSX-listed British Columbia–based Neovasc Inc., with a total transaction value of up to US$147 million;
  • Bruker, a Nasdaq-listed provider of scientific instruments and analytical and diagnostic solutions, in its acquisition of Neurescence Inc., a Toronto-based innovative provider of optical functional neuroimaging;
  • IDEXX Laboratories, Inc., a Nasdaq-listed leader in the design, development and marketing of diagnostic test instruments, in its acquisition of Pathogen Detection Systems, Inc., a Canadian-based developer of microbiological testing systems;
  • KKR as Canadian counsel in its equity investment in the strategic merger of 123Dentist with Altima Dental and Lapointe Group, creating one of the largest dental support organizations in Canada; and
  • Knight Therapeutics Inc., a pan-America specialty pharmaceutical company, in its exclusive license and supply agreements with Rigel Pharmaceuticals, a biotechnology company based in the United States, to commercialize fostamatinib throughout Latin America.

The following Davies partners are recognized in this year’s guide: